Non-hodgkin's%20lymphoma Treatment

Treatment

Transplantation

Further studies are needed to support use of bone marrow transplant (BMT) in high-risk NHL patients
Treatment of choice for patients with aggressive recurrent NHL
Studies show improved survival (20-40% long-term disease-free rate) in high-risk patients
Autologous stem cell rescue therapy (ASCRT) after high-dose therapy (HDT) is recommended in the following:
- Consolidation after aggressive treatment of MCL
- Consolidation/additional treatment of DLBCL and BL with partial or complete response after 2nd-line therapy
- 2nd-line or extended dosing of FL and MZL
Allogeneic hematopoietic cell transplant may be used in the 2nd-line consolidation treatment of FL, BL, DLBCL, MZL and MCL, and as additional therapy in patients with acute ATLL
May be considered in patients with indolent recurrent NHL, and aggressive noncontiguous stage II/III/IV NHL
- Studies show an increase in the progression-free survival rate of patients given SCT as compared to those given chemotherapy alone

New treatment option now available for patients with HR+/HER2- aBC/MBC, PIK3CA mutations

31 Mar 2021

At the recent webinar entitled Pik Me Up: Mutation Matters, Consultant Medical Oncologist Dr Senthil Rajappa discussed the role of PI3Kα-specific inhibitor alpelisib (TREZILENT^®, Novartis) in managing patients with HR+/HER2- aBC/MBC and PIK3CA mutations while Senior Consultant Pathologist Professor Dr Pathmanathan Rajadurai explained the process of detecting PIK3CA mutations in patients.

The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib

Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021

In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).